Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Persistent Toxoplasma Infection of the Brain Induced Neurodegeneration Associated with Activation of Complement and Microglia.

Li Y, Severance EG, Viscidi RP, Yolken RH, Xiao J.

Infect Immun. 2019 Jul 23;87(8). pii: e00139-19. doi: 10.1128/IAI.00139-19. Print 2019 Aug.

PMID:
31182619
2.

Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy.

Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, Viscidi RP, Burke AE, Ravel J, Gravitt PE.

Menopause. 2018 Nov;25(11):1321-1330. doi: 10.1097/GME.0000000000001236.

PMID:
30358729
3.

Chronic Toxoplasma gondii Infection Induces Anti-N-Methyl-d-Aspartate Receptor Autoantibodies and Associated Behavioral Changes and Neuropathology.

Li Y, Viscidi RP, Kannan G, McFarland R, Pletnikov MV, Severance EG, Yolken RH, Xiao J.

Infect Immun. 2018 Sep 21;86(10). pii: e00398-18. doi: 10.1128/IAI.00398-18. Print 2018 Oct.

4.

PD-1 immune checkpoint blockade promotes brain leukocyte infiltration and diminishes cyst burden in a mouse model of Toxoplasma infection.

Xiao J, Li Y, Yolken RH, Viscidi RP.

J Neuroimmunol. 2018 Jun 15;319:55-62. doi: 10.1016/j.jneuroim.2018.03.013. Epub 2018 Mar 30.

PMID:
29685290
5.

Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.

Jiang RT, Wang JW, Peng S, Huang TC, Wang C, Cannella F, Chang YN, Viscidi RP, Best SRA, Hung CF, Roden RBS.

J Virol. 2017 Jul 12;91(15). pii: e00699-17. doi: 10.1128/JVI.00699-17. Print 2017 Aug 1.

6.

Behavioral Abnormalities in a Mouse Model of Chronic Toxoplasmosis Are Associated with MAG1 Antibody Levels and Cyst Burden.

Xiao J, Li Y, Prandovszky E, Kannan G, Viscidi RP, Pletnikov MV, Yolken RH.

PLoS Negl Trop Dis. 2016 Apr 28;10(4):e0004674. doi: 10.1371/journal.pntd.0004674. eCollection 2016 Apr.

7.

Human Papillomavirus (HPV) L1 Serum Antibodies and the Risk of Subsequent Oral HPV Acquisition in Men: The HIM Study.

Pierce Campbell CM, Viscidi RP, Torres BN, Lin HY, Fulp W, Abrahamsen M, Lazcano-Ponce E, Villa LL, Kreimer AR, Giuliano AR.

J Infect Dis. 2016 Jul 1;214(1):45-8. doi: 10.1093/infdis/jiw083. Epub 2016 Feb 29.

8.

Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer.

Fakhry C, Qualliotine JR, Zhang Z, Agrawal N, Gaykalova DA, Bishop JA, Subramaniam RM, Koch WM, Chung CH, Eisele DW, Califano J, Viscidi RP.

Cancer Prev Res (Phila). 2016 Feb;9(2):135-41. doi: 10.1158/1940-6207.CAPR-15-0299. Epub 2015 Dec 23.

9.

Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Wang JW, Jagu S, Wu WH, Viscidi RP, Macgregor-Das A, Fogel JM, Kwak K, Daayana S, Kitchener H, Stern PL, Gravitt PE, Trimble CL, Roden RB.

Clin Vaccine Immunol. 2015 Jul;22(7):806-16. doi: 10.1128/CVI.00799-14. Epub 2015 May 13.

10.

Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas.

Hampras SS, Viscidi RP, Helzlsouer KJ, Lee JH, Fulp WJ, Giuliano AR, Platz EA, Rollison DE.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2591-6. doi: 10.1158/1055-9965.EPI-14-0370. Epub 2014 Aug 15.

11.

HIV-1, HBV, HCV, HTLV, HPV-16/18, and Treponema pallidum infections in a sample of Brazilian men who have sex with men.

Soares CC, Georg I, Lampe E, Lewis L, Morgado MG, Nicol AF, Pinho AA, Salles RC, Teixeira SL, Vicente AC, Viscidi RP, Gomes SA.

PLoS One. 2014 Aug 1;9(8):e102676. doi: 10.1371/journal.pone.0102676. eCollection 2014.

12.

Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy.

Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, Viscidi RP, Burke AE, Ravel J, Gravitt PE.

Menopause. 2014 May;21(5):450-8. doi: 10.1097/GME.0b013e3182a4690b.

13.

Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen.

Gomez B, He L, Tsai YC, Wu TC, Viscidi RP, Hung CF.

Cell Biosci. 2013 Jul 15;3(1):29. doi: 10.1186/2045-3701-3-29.

14.

Obesity and human papillomavirus infection in perimenopausal women.

Liu SH, Rositch AF, Viscidi RP, Silver MI, Burke AE, Gravitt PE.

J Infect Dis. 2013 Oct 1;208(7):1071-80. doi: 10.1093/infdis/jit297. Epub 2013 Jul 9.

15.

Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and uninfected women from Brazil.

Nicol AF, Grinsztejn B, Friedman RK, Veloso VG, Cunha CB, Georg I, Pilotto JH, Moreira RI, Castro CA, Silver B, Viscidi RP.

J Clin Virol. 2013 Jun;57(2):147-51. doi: 10.1016/j.jcv.2013.02.007. Epub 2013 Mar 9.

PMID:
23490398
16.

A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States.

Gravitt PE, Rositch AF, Silver MI, Marks MA, Chang K, Burke AE, Viscidi RP.

J Infect Dis. 2013 Jan 15;207(2):272-80. doi: 10.1093/infdis/jis660. Epub 2012 Dec 12.

17.

The Toxoplasma MAG1 peptides induce sex-based humoral immune response in mice and distinguish active from chronic human infection.

Xiao J, Viscidi RP, Kannan G, Pletnikov MV, Li Y, Severance EG, Yolken RH, Delhaes L.

Microbes Infect. 2013 Jan;15(1):74-83. doi: 10.1016/j.micinf.2012.10.016. Epub 2012 Nov 7.

18.

Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen.

Gomez BP, Wang C, Viscidi RP, Peng S, He L, Wu TC, Hung CF.

Cell Biosci. 2012 Oct 24;2(1):36. doi: 10.1186/2045-3701-2-36.

19.

Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women.

Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE.

Cancer Res. 2012 Dec 1;72(23):6183-90. doi: 10.1158/0008-5472.CAN-12-2635. Epub 2012 Sep 27.

20.

Antibody response to Merkel cell polyomavirus associated with incident lymphoma in the Epilymph case-control study in Spain.

Robles C, Poloczek A, Casabonne D, Gonzalez-Barca E, Bosch R, Benavente Y, Viscidi RP, de Sanjosé S.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1592-8. doi: 10.1158/1055-9965.EPI-11-1140. Epub 2012 Jul 10.

21.

Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men.

Lu B, Viscidi RP, Wu Y, Nyitray AG, Villa LL, Lazcano-Ponce E, Carvalho da Silva RJ, Baggio ML, Quiterio M, Salmerón J, Smith DC, Abrahamsen M, Papenfuss M, Giuliano AR.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1542-6. doi: 10.1158/1055-9965.EPI-12-0483. Epub 2012 Jul 3.

22.

Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients.

Pastrana DV, Brennan DC, Cuburu N, Storch GA, Viscidi RP, Randhawa PS, Buck CB.

PLoS Pathog. 2012;8(4):e1002650. doi: 10.1371/journal.ppat.1002650. Epub 2012 Apr 12.

23.

Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Tiggelaar SM, Lin MJ, Viscidi RP, Ji J, Smith JS.

J Adolesc Health. 2012 Feb;50(2):110-31. doi: 10.1016/j.jadohealth.2011.10.010. Review.

24.

Development of a DNA vaccine targeting Merkel cell polyomavirus.

Zeng Q, Gomez BP, Viscidi RP, Peng S, He L, Ma B, Wu TC, Hung CF.

Vaccine. 2012 Feb 8;30(7):1322-9. doi: 10.1016/j.vaccine.2011.12.072. Epub 2011 Dec 29.

25.

Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men.

Lu B, Viscidi RP, Wu Y, Lee JH, Nyitray AG, Villa LL, Lazcano-Ponce E, da Silva RJ, Baggio ML, Quiterio M, Salmeron J, Smith DC, Abrahamsen ME, Papenfuss MR, Stockwell HG, Giuliano AR.

Cancer Res. 2012 Feb 1;72(3):676-85. doi: 10.1158/0008-5472.CAN-11-0751. Epub 2011 Nov 28.

26.

Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women.

Marks MA, Viscidi RP, Chang K, Silver M, Burke A, Howard R, Gravitt PE.

Cytokine. 2011 Dec;56(3):798-803. doi: 10.1016/j.cyto.2011.09.012. Epub 2011 Oct 19.

27.

Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus.

Viscidi RP, Rollison DE, Sondak VK, Silver B, Messina JL, Giuliano AR, Fulp W, Ajidahun A, Rivanera D.

Clin Vaccine Immunol. 2011 Oct;18(10):1737-43. doi: 10.1128/CVI.05175-11. Epub 2011 Aug 31.

28.

JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals.

Viscidi RP, Khanna N, Tan CS, Li X, Jacobson L, Clifford DB, Nath A, Margolick JB, Shah KV, Hirsch HH, Koralnik IJ.

Clin Infect Dis. 2011 Oct;53(7):711-5. doi: 10.1093/cid/cir507. Epub 2011 Aug 18.

29.

Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study).

Lu B, Viscidi RP, Lee JH, Wu Y, Villa LL, Lazcano-Ponce E, da Silva RJ, Baggio ML, Quiterio M, Salmerón J, Smith DC, Abrahamsen M, Papenfuss M, Stockwell HG, Giuliano AR.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):990-1002. doi: 10.1158/1055-9965.EPI-10-1160. Epub 2011 Mar 4.

30.

Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort.

Safaeian M, Quint K, Schiffman M, Rodriguez AC, Wacholder S, Herrero R, Hildesheim A, Viscidi RP, Quint W, Burk RD.

J Natl Cancer Inst. 2010 Dec 1;102(23):1794-804. doi: 10.1093/jnci/djq436. Epub 2010 Nov 23.

31.

Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles.

Pejawar-Gaddy S, Rajawat Y, Hilioti Z, Xue J, Gaddy DF, Finn OJ, Viscidi RP, Bossis I.

Cancer Immunol Immunother. 2010 Nov;59(11):1685-96. doi: 10.1007/s00262-010-0895-0. Epub 2010 Jul 21.

32.

Discrepant findings in immune responses to JC virus in patients receiving natalizumab.

Tan CS, Chen Y, Viscidi RP, Kinkel RP, Stein MC, Koralnik IJ.

Lancet Neurol. 2010 Jun;9(6):565-6; author reply 566-7. doi: 10.1016/S1474-4422(10)70124-1. No abstract available.

33.

Adult male circumcision: will it reduce disease caused by human papillomavirus?

Viscidi RP, Shah KV.

J Infect Dis. 2010 May 15;201(10):1447-9. doi: 10.1086/652186. No abstract available.

PMID:
20370482
34.

Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial.

Sutcliffe S, Viscidi RP, Till C, Goodman PJ, Hoque AM, Hsing AW, Thompson IM, Zenilman JM, De Marzo AM, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):614-8. doi: 10.1158/1055-9965.EPI-09-1080.

35.

Population dynamics of Neisseria gonorrhoeae in Shanghai, China: a comparative study.

Tazi L, Pérez-Losada M, Gu W, Yang Y, Xue L, Crandall KA, Viscidi RP.

BMC Infect Dis. 2010 Jan 21;10:13. doi: 10.1186/1471-2334-10-13.

36.

Asymptomatic reactivation of JC virus in patients treated with natalizumab.

Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ.

N Engl J Med. 2009 Sep 10;361(11):1067-74. doi: 10.1056/NEJMoa0904267. Erratum in: N Engl J Med. 2011 May 12;364(19):1882.

37.

Correlates of sexually transmitted infection histories in a cohort of American male health professionals.

Sutcliffe S, Kawachi I, Alderete JF, Gaydos CA, Jacobson LP, Jenkins FJ, Viscidi RP, Zenilman JM, Platz EA.

Cancer Causes Control. 2009 Nov;20(9):1623-34. doi: 10.1007/s10552-009-9409-9. Epub 2009 Aug 5.

38.

Serological pattern consistent with infection with type I Toxoplasma gondii in mothers and risk of psychosis among adult offspring.

Xiao J, Buka SL, Cannon TD, Suzuki Y, Viscidi RP, Torrey EF, Yolken RH.

Microbes Infect. 2009 Nov;11(13):1011-8. doi: 10.1016/j.micinf.2009.07.007. Epub 2009 Jul 26.

PMID:
19638313
39.

Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons.

Wüthrich C, Dang X, Westmoreland S, McKay J, Maheshwari A, Anderson MP, Ropper AH, Viscidi RP, Koralnik IJ.

Ann Neurol. 2009 Jun;65(6):742-8. doi: 10.1002/ana.21619.

40.

Pretransplant IgG antibodies to polyoma BK virus in pediatric renal transplants.

Bijol V, Cimic A, Viscidi RP, Hymes LC.

Pediatr Transplant. 2010 Mar;14(2):224-7. doi: 10.1111/j.1399-3046.2009.01201.x. Epub 2009 May 30.

PMID:
19496978
41.

Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms.

Severance EG, Dickerson FB, Viscidi RP, Bossis I, Stallings CR, Origoni AE, Sullens A, Yolken RH.

Schizophr Bull. 2011 Jan;37(1):101-7. doi: 10.1093/schbul/sbp052. Epub 2009 Jun 2.

42.

Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients.

Grabowski MK, Viscidi RP, Margolick JB, Jacobson LP, Shah KV.

J Med Virol. 2009 Jul;81(7):1140-50. doi: 10.1002/jmv.21493.

43.

Clinician's guide to human papillomavirus immunology: knowns and unknowns.

Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D.

Lancet Infect Dis. 2009 Jun;9(6):347-56. doi: 10.1016/S1473-3099(09)70108-2. Review.

PMID:
19467474
44.

Prospective study of JC virus seroreactivity and the development of colorectal cancers and adenomas.

Rollison DE, Helzlsouer KJ, Lee JH, Fulp W, Clipp S, Hoffman-Bolton JA, Giuliano AR, Platz EA, Viscidi RP.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1515-23. doi: 10.1158/1055-9965.EPI-08-1119. Epub 2009 Apr 21.

45.

Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population.

Severance EG, Bossis I, Dickerson FB, Stallings CR, Origoni AE, Sullens A, Yolken RH, Viscidi RP.

Clin Vaccine Immunol. 2008 Dec;15(12):1805-10. doi: 10.1128/CVI.00124-08. Epub 2008 Oct 22.

46.

Sexually transmissible infections and prostate cancer risk.

Huang WY, Hayes R, Pfeiffer R, Viscidi RP, Lee FK, Wang YF, Reding D, Whitby D, Papp JR, Rabkin CS.

Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2374-81. doi: 10.1158/1055-9965.EPI-08-0173.

47.

Cancer. A skin cancer virus?

Viscidi RP, Shah KV.

Science. 2008 Feb 22;319(5866):1049-50. doi: 10.1126/science.1155048. No abstract available.

PMID:
18292327
48.

Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland.

Görander S, Lagergård T, Romanik M, Viscidi RP, Martirosian G, Liljeqvist JA.

Clin Vaccine Immunol. 2008 Apr;15(4):675-80. doi: 10.1128/CVI.00260-07. Epub 2008 Feb 20.

49.

Disease progression and evolution of the HIV-1 env gene in 24 infected infants.

Carvajal-Rodríguez A, Posada D, Pérez-Losada M, Keller E, Abrams EJ, Viscidi RP, Crandall KA.

Infect Genet Evol. 2008 Mar;8(2):110-20. doi: 10.1016/j.meegid.2007.10.009. Epub 2007 Nov 1.

PMID:
18249158
50.

Human papillomavirus seroprevalence among young male and female drug users.

Plitt SS, Sherman SG, Viscidi RP, Strathdee SA, Fuller CM, Taha TE.

Sex Transm Dis. 2007 Sep;34(9):676-80.

PMID:
17847165

Supplemental Content

Loading ...
Support Center